RxDoctor Payments Data

Charleen Gonden

Psychiatric/Mental Health · Berlin, MDNPI 1255822565

Payments from drug & device makers

$822in general payments, 2019–2025

Across 23 payments — averaging $35.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$280
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
  • Alkermes, Inc.$125
  • Lundbeck LLC$94
  • AbbVie$56
  • Otsuka America Pharmaceutical, Inc.$39
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$67482%
  • Education$14918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$822 in reported general payments places this provider in the 65th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$139,070
Medicare patients
87
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl86$133,502
IngrezzaValbenazine Tosylate15$115,957
RexultiBrexpiprazole101$68,301
Abilify MaintenaAripiprazole14$38,041
VraylarCariprazine Hcl22$32,272
LatudaLurasidone Hcl12$21,108
Aripiprazole128$12,044
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$11,130
Lurasidone Hcl16$8,585
Varenicline Tartrate27$7,931
Clozapine91$5,762
BelsomraSuvorexant14$5,692
Chlorpromazine Hcl30$4,817
Quetiapine Fumarate240$4,398
ConcertaMethylphenidate Hcl11$4,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Concerta$280$137,85297 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$39$106,343115 claims
AbbVieVraylar$56$32,27222 claims
Indivior Inc.Suboxone$22$11,13014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Berlin

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →